# Novo Nordisk is seeing brisk early demand for its new weight-loss pill.

*biotech · news · 2026-05-05 · The Hindu Business Line*

## Key points

- Novo's oral Wegovy pill reached about 721,000 U.S. prescriptions in Q1, beating expectations.
- IQVIA data suggest actual prescription numbers may be higher, excluding some telehealth channels.
- Approximately 450,000 prescriptions were for the cheapest starter dose, potentially reducing overall revenue.
- The introduction of Eli Lilly's rival pill, Foundayo, in April ended Novo's U.S. exclusivity.
- Analysts warn strong prescription growth may mask revenue impact from slow dose escalation and price pressures.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** Denmark, United States

[Read the full story on The Hindu Business Line](https://www.thehindubusinessline.com/companies/novo-nordisks-weight-loss-pill-boom-faces-price-war-test/article70941749.ece)

---

Canonical: https://newsio.io/n/4c35e1c8-b8f5-4ac1-997f-c3aff82b9335/novo-nordisk-is-seeing-brisk-early-demand-for-its-new-weight-loss-pill-investors
Summarized by Newsio from The Hindu Business Line. https://newsio.io/how-it-works